EGFR and breast cancer: Hypoxic human breast cancer cells (2 million) were injected into female nu/nu mice for tumor inoculation, followed by treatment with paclitaxel- and lonidamine-loaded EGFR-targeted NPs, paclitaxel- and lonidamine-loaded non-targeted NPs, and paclitaxel and ionidamine solution.